Podcasts about cancer care

In this episode, Robert A. Figlin, MD, FACP, Steven Spielberg Family Chair in Hematology Oncology and Interim Director of Cedars-Sinai Cancer and the Samuel Oschin Comprehensive Cancer Institute, discusses aligning cancer strategy with system priorities, embedding research into clinical care, and building innovative, patient centered models to improve access and outcomes across the continuum.

In this episode, Robert A. Figlin, MD, FACP, Steven Spielberg Family Chair in Hematology Oncology and Interim Director of Cedars-Sinai Cancer and the Samuel Oschin Comprehensive Cancer Institute, discusses aligning cancer strategy with system priorities, embedding research into clinical care, and building innovative, patient centered models to improve access and outcomes across the continuum.

In honor of TNBC Day, CancerCare is proud to partner with the TNBC Foundation for a special episode of Cancer Out Loud dedicated to the triple-negative breast cancer community.We would love to hear from you! Please share your thoughts or episode ideas at ⁠⁠⁠⁠⁠canceroutloud@cancercare.org⁠⁠⁠⁠⁠ or leave a comment on this episode!Please follow, rate and share Cancer Out Loud to help others find strength and support through our community.SummaryIn this conversation, CancerCare oncology social worker Christina Monaco, and Caryn Sullivan, a breast cancer survivor and thriver, discuss the importance of support and community for individuals diagnosed with triple negative breast cancer. Caryn shares her personal journey through various stages of breast cancer, emphasizing the significance of hope, positivity, and wellness practices. They explore the role of caregivers, the impact of community resources like the Triple Negative Breast Cancer Foundation, and the importance of mindfulness in navigating the challenges of cancer treatment.TakeawaysCaryn's journey with breast cancer began with an early stage diagnosis.She emphasizes the importance of support from family and friends during treatment.Caryn's cancer mutated to triple negative metastatic breast cancer after several years.Finding hope and positivity is crucial in the cancer journey.Community support, such as the TNBC Foundation, plays a vital role in coping with cancer.Wellness practices, including mindfulness and healthy eating, have helped Caryn manage her health.Building relationships with medical professionals is essential for effective treatment.Caregivers should be mindful of the needs of those they support.Caryn encourages newly diagnosed patients to seek out success stories for inspiration.Gratitude practices can help shift focus during difficult times.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlighted the need for oncologists to recognize and address depression for patients with cancer. In a new episode of Oncology on the Go created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, spoke with Boris Kiselev, MD. Together, they explored the complex intersection of oncology and psychiatry. The conversation challenged the oversimplification of “cancer-related sadness” to provide clinicians with a framework for distinguishing between normative grief and clinical Major Depressive Disorder (MDD).The conversation focused on: The Diagnostic Continuum: Depression exists on a spectrum ranging from normative sadness—encompassing a healthy, waxing-and-waning response to trauma—to pathological MDD. Differentiating Grief vs Depression:  Grief/Normative Sadness: Often occurs in waves, improves over time, and does not typically affect a patient's functional ability. It is often a response to the loss of one's “pre-cancer self”.   Clinical Depression: Marked by anhedonia (loss of pleasure), persistent feelings of guilt or worthlessness, and a fundamental change in identity where the patient no longer “feels like themselves”.   The “Quantum” Observation Effect: Patients often present differently to oncologists than they do to mental health professionals. In the oncology clinic, patients may unconsciously “shield” their distress to ensure that their treatment plan remains unchanged. The Power of the Story: The experts emphasized that the oncologist-patient relationship is therapeutic. Allowing patients to “tell their story” rather than jumping straight to clinical data builds trust with them and uncovers hidden psychological pressure points. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor in the Psycho-oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in Internal Medicine.

The doctors detail real-world results for cardiovascular disease, neurodegeneration, Lyme, and cancer using non-invasive therapies. #ChronicDisease #NaturalMedicine #HealingProtocols

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Susana M. Campos, MD, MPH. Dr Campos is the clinical director and director of Educational Initiatives for the of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an institute physician and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Drs Matulonis and Campos discussed the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.According to 2026 estimates from the American Cancer Society, approximately 13,400 new cases of invasive cervical cancer will be diagnosed in the United States, with roughly 4200 deaths. Although incidence has declined over time due to human papillomavirus (HPV) vaccination and screening efforts, rates have plateaued, and the disease burden remains substantial, particularly among women aged 35 to 64 years. Dr Campos noted that approximately half of cases occur in women younger than 50 years of age, and about 20% are diagnosed in women older than 65 years of age.Dr Campos reviewed common presenting symptoms, including abnormal vaginal bleeding, intermenstrual or postmenopausal bleeding, abnormal discharge, pelvic pain, and, in advanced cases, urinary symptoms or leg swelling. She explained that diagnosis begins with pelvic examination and cervical cytology or HPV testing, followed by colposcopy and biopsy when indicated. Although cervical cancer remains one of the few malignancies that is clinically staged, imaging modalities, such as MRI, CT, and PET scans, are critical to accurately defining disease extent, they underscored. Moreover, the discussion highlighted transformative advances in locally advanced disease. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated improved progression-free and overall survival with the addition of pembrolizumab (Keytruda) to standard chemoradiation, establishing a new standard for high-risk patients, Campos stated. Similarly, the phase 3 INTERLACE trial (NCT01566240) showed that short-course induction chemotherapy with carboplatin and paclitaxel before chemoradiation improved long-term outcomes. Campos forecasted that ongoing studies, including the phase 3 NRG-GY037 trial (NCT07061977), may integrate these approaches and further refine optimal treatment sequencing.Lastly, Drs Matulonis and Campos highlighted the expanding therapeutic arsenal in the recurrent and metastatic setting. Campos noted how antibody-drug conjugates, such as tisotumab vedotin-tftv (Tivdak) and fam-trastuzumab deruxtecan-nxki (Enhertu), have demonstrated meaningful activity, particularly in biomarker-selected populations. Campos added that investigational strategies targeting TROP2, such as sacituzumab govitecan-hziy (Trodelvy), represent additional promising avenues.Despite these advances, both experts emphasized that prevention remains paramount. Widespread uptake of HPV vaccination, including the 9-valent vaccine, as well as adherence to routine cervical screening, are essential to reducing the long-term burden of this largely preventable disease.

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

This new episode of the award-winning Let's Talk Cancer builds on the recent World Cancer Day campaign theme 'United by Unique' about people-centred cancer care, exploring how comprehensive support can transform the breast cancer journey for women in Egypt and across the region.Cary Adams speaks with Dr Yomna Sherif, Patient Navigation Manager and breast surgeon at the Baheya Foundation in Egypt, a UICC member organisation dedicated to improving outcomes for women with breast cancer, and winner of the World Cancer Day Campaign award in 2024.Together, they look at how Baheya puts people-centred care into practice through services such as patient navigation, practical skills support, and help with transport and accommodation – and how patient-led organisations can shape more responsive, compassionate cancer services in their countries and beyond. Hosted on Acast. See acast.com/privacy for more information.

Send a textIn this episode of Functional Medicine Bitesized, I had the opportunity to sit down with Chris Fitzmaurice, clinical exercise physiologist at the University of Miami Health System and certified cancer exercise specialist, to explore the powerful role of exercise as medicine in cancer care.It was a fascinating chat unpacking how aerobic and resistance training act as “molecular medicine”—modulating inflammation, supporting the immune system, and changing the tumor microenvironment to make standard treatments like chemotherapy and radiation more effective and better tolerated. Chris used a brilliant analogy explaining how exercise can be thought of as turning the tumor's “paradise beach” into “Antarctica,” disrupting its ability to thrive.Listen in to hear more about personalised exercise prescription for different cancer types and stages, the emerging science of myokines and exerkines as well as the mental health impact of movement, including how exercise can prevent and treat depression in cancer survivorsWe also discussed highly practical strategies including one of my all time favourites, "exercise snacks" and why, when it comes to exercise, anything is better than nothing. Links mentioned in this episode@exercisebeatdiseases https://www.linkedin.com/in/christopher-fitzmaurice-ms-cep-cscs-cet-106b5633?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_appThanks for listening to our podcast and please feel free to get in touch: Tweet us at @fmedassociates Follow us on Instagram or Facebook @petewilliams_fma Email us on info@fm.associates For more information about our services please visit our website www.functional-medicine.associates We would love to hear from you!

We would love to hear from you! Please share your thoughts or episode ideas at ⁠⁠⁠⁠canceroutloud@cancercare.org⁠⁠⁠⁠ or leave a comment on this episode!Please follow, rate and share Cancer Out Loud to help others find strength and support through our community.SummaryIn this episode of Cancer Out Loud, CancerCare social worker Christina Monaco and Alexa Dashko, an Oncology Dietitian, discuss the vital role of nutrition in cancer care. They explore the emotional aspects of dietary choices, common misconceptions about food and cancer, and the importance of setting boundaries during treatment. The conversation also addresses food access issues, cultural considerations in nutrition, and the significance of community support. Listeners are encouraged to seek help from dietitians and to prioritize their own needs during their cancer journey.TakeawaysNutrition impacts emotional and mental health during cancer treatment.Patients often feel overwhelmed by dietary advice and need clear guidance.Setting boundaries with family during meals is crucial for comfort.Common misconceptions about diet can lead to unnecessary stress for patients.Food access issues can significantly affect a patient's ability to maintain nutrition.Cultural preferences should be respected in dietary recommendations.Patients should feel empowered to advocate for their nutritional needs.Community support plays a vital role in a patient's journey.Dietitians are accessible resources for cancer patients.It's important to focus on what patients can eat rather than what they can't.

Psychology Month continues with a look at psychology's role in cancer care. A diagnosis of cancer will affect each person who receives one a little differently. But it will affect everyone. Not just the person with the diagnosis, but the people around them. Family, friends, and co-workers need help as well. Psychologists can play a central role at every stage, from diagnosis to treatment to end-of-life care. Our guests on Mind Full today are friends. Bob Wakeham met Dr. Sheila Garland when he joined her study on insomnia in people who had been diagnosed with cancer. Bob shares his story and experiences with us, and tells us how Sheila's involvement in his life made an enormous difference. Canadian Association of Psychosocial Oncology: https://www.capo.ca/

Welcome to Share The Tea Tuesday's. Cancer Care Series let's talk for a quick moment about cancer prevention. Let's TALK! If you would like to be a special guest, send us an email sharetheteawithv@gmail.com and we will get you scheduled. Thank you for listening to Share The Tea Tuesday's. Follow us on social media @sharetheteawithv Be Intentional, Insightful and IMPACTful. Share The Tea, Don't Spill It.#ShareTheTea #LIve2Learn #TeaTuesday #Podcast #SnTEAEnterprise #OklahomaEvents

Love the episode? Send us a text!What if part of what makes cancer so hard isn't just the diagnosis—but the spaces where care happens?In this eye-opening episode of Breast Cancer Conversations, host Laura Carfang explores how hospital design, architecture, and the built environment directly shape the cancer experience, often in ways patients never realize—but deeply feel.Laura is joined by Abbie Clary, Executive Director of Market Strategies and Growth for Health for All, and a nationally recognized leader in healthcare architecture and experience design. With millions of square feet of cancer and healthcare facilities in her portfolio—including projects at Memorial Sloan Kettering, MD Anderson, and the Shirley Ryan AbilityLab—Abbie pulls back the curtain on how hospitals are designed, who they're designed for, and why women are so often treated as the “outlier.”Together, they discuss trauma-informed design, survivorship-centered care, caregiver inclusion, gender bias in medical spaces, and why healing doesn't only happen through medicine—it happens through dignity, control, and environment.In This Episode, We Talk About:Why hospitals and medical spaces are often designed for a “default male”How architecture impacts anxiety, trauma, and healing for cancer patientsWhat trauma-informed design actually looks like in practiceWhy cancer patients experience healthcare differently than other patientsThe importance of designing for repeat visits, not one-time careHow caregivers and loved ones should be treated as part of the care teamWhy dignity, control, and privacy matter as much as efficiencyGender bias in medical design—from gowns to equipment to workflowsWhy women's pain and discomfort are often minimized in healthcareDesigning cancer centers for survivorship, not just treatmentAbout Today's GuestAbbie Clary, FAIA, FACHA, is the Executive Director of Market Strategies and Growth — Health for All. Her work spans some of the most ambitious healthcare projects in the world, including Memorial Sloan Kettering's new Cancer Care Pavilion, MD Anderson Cancer Center's 2030 facilities master plan, and the Shirley Ryan AbilityLab in Chicago.A nationally sought-after speaker and TEDx presenter, Abbie's work focuses on transforming healthcare through strategic, human-centered design—bridging architecture, culture change, patient experience, and health equity. Her mission is simple but radical: design healthcare spaces that actually support healing, dignity, and belonging. Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.

Photobiomodulation (PBM) is a light-based therapy that uses specific wavelengths to interact with body tissues, influencing cellular activity without heat and supporting recovery across both medical and general wellness settings Europe recently released its first formal clinical guide for PBM in oncology, marking a shift toward standardized use of light-based supportive care across cancer treatment centers Clinical research shows PBM is most strongly supported for managing oral mucositis and radiation-related skin damage, two common cancer complications that can interfere with eating, speaking, and treatment continuity Beyond cancer care, PBM has been studied for wound healing, nerve pain, musculoskeletal recovery, skin health, and hair loss, with consensus reviews supporting its safety when properly applied Effective PBM depends on correct wavelength selection, dosing, and device quality, with red and near-infrared light delivering biologically active energy when used within established therapeutic ranges

In this episode, Thomas Graf, MD, Chief Medical Officer for Florida Blue, part of GuideWell, shares how the health plan is improving cancer care through a high-touch, tech-enabled navigation program for Medicare Advantage members. He discusses reducing variation, closing gaps between diagnosis and treatment, and achieving better outcomes, higher satisfaction, and lower costs by centering care around the patient experience.

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

In this episode, Dr. Paul Wheatley-Price chats with Dr. Lisa Hicks, a hematologist-oncologist at St. Michael's Hospital, who specializes in caring for medically and socially complex people with blood cancer. They talk about the unique neighbourhood that she serves in downtown Toronto, what are the social determinants of health, how various aspects of poverty and societal inequity might impact those with a lung cancer (or other cancer) diagnosis.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

Is Artificial Intelligence actually helping cancer patients, or is it just noise? In this episode of The Patient From Hell, Samira sits down with Dr. Shadi Nabhan to separate the Hype from the Reality in 2026.We discuss the massive evolution in oncology—from the "library days" of 1995 to the AI-driven diagnostics of today. Dr. Shadi shares his "Airport Analogy" for navigating a cancer diagnosis, offers a life-changing reframe on how we view advanced disease (it's not just "curable" vs. "terminal"—it can be "controllable"), and gives his #1 piece of advice for selecting a medical team that will actually show up for you when things get hard.Key Topics Discussed:AI in 2026: How doctors use AI to simplify complex terms like CAR T-cell therapy and why patients need to "trust but verify" AI-generated medical advice.The "Controllable" Reframe: Why treating metastatic cancer like diabetes or hypertension changes the patient experience.Navigating the "Airport": Why the healthcare system feels like being dropped in a foreign airport without a map.Advice for the Industry: What Healthcare Systems and Pharma companies need to change right now regarding clinical trials and drug pricing.About Today's Guest Dr. Chadi Nabhan:Dr. Chadi Nabhan is a board-certified hematologist, oncologist, and the Chief Medical Officer at Ryght, Inc., where he leads the integration of Generative AI into clinical research to accelerate the delivery of lifesaving therapies. With a career spanning leadership roles at Caris Life Sciences and the University of Chicago, Dr. Nabhan is a prolific researcher with over 300 publications and a prominent author whose work focuses on the intersection of medicine, justice, and technology.AI Visionary: Leading the charge in using AI to optimize clinical trials and patient outcomes.Expert Clinician: Trained at Northwestern and Harvard, with decades of experience in malignant hematology.Renowned Author: Published three books with Johns Hopkins University Press, including The Cancer Journey and the forthcoming AI and Cancer Care (2026).Podcast Host: Voice of the popular weekly series Healthcare Unfiltered.Quotes from the Episode:"We cure more patients than we have ever dreamt of... Women who are affected by breast cancer today are more likely to be completely cured." "Availability is key. Are they going to really pick up the phone and talk to you when you need them?"00:00 - The reality of the cancer journey (It's not smooth sailing)01:00 - Intro: Dr. Shadi Nabhan & The Fun Factor01:25 - AI in Healthcare: Hype, Hope, and Reality04:15 - How doctors use AI to explain complex therapies06:38 - Warning for patients using AI: "Garbage in, Garbage out"08:45 - The Evolution of Medicine: 1995 vs. 202613:00 - The "Airport Analogy": Why patients feel lost17:30 - MUST WATCH: Reframing "Terminal" cancer as "Controllable"21:30 - Advice for Healthcare Leaders: Agility & Patient Involvement23:50 - Advice for Pharma: Drug Pricing & Accelerating Innovation26:00 - The #1 criteria for picking your medical team28:18 - The importance of Second Opinions28:50 - What to expect in late 2026: AI in Cancer Care Book

Dr. Saupe introduces a terrain-based approach to cancer rooted in vitality, energy balance, and ancient holistic wisdom. #HolisticCancer #VitalityHealing #NaturopathicMedicine #HealthTalks

In this episode, Thomas Graf, MD, Chief Medical Officer for Florida Blue, part of GuideWell, shares how the health plan is improving cancer care through a high-touch, tech-enabled navigation program for Medicare Advantage members. He discusses reducing variation, closing gaps between diagnosis and treatment, and achieving better outcomes, higher satisfaction, and lower costs by centering care around the patient experience.

The Yeah C'mon Show 02/10/2026 - Atlanta Cancer Care Foundation. Steve welcomes Rick Barrick from the ACCF to discuss the upcoming event Steve will host at The Rock N Taco in Roswell, GA Sunday, February 15th.

Dr. Lori Bouchard joins Leigh Ann to discuss her journey into cancer care, emphasizing the metabolic approach to treatment. She highlights the importance of personalized treatment plans, the role of mindset in healing, and the significance of detoxification. The discussion also covers various integrative therapies and the emotional aspects of cancer recovery, ultimately focusing on finding joy and purpose in the healing journey.Product Discount Codes + LinksRe-Align Your Life WorkshopJuna: Website (Discount Code: LEIGHANN)Broc Shot: Website (Discount Code: LEIGHANNLINDSEY)Hoolest: Website (Discount Code: THEACCRESCENT10)Episode Links Book: Live Longer & Stronger w/Breast CancerBook: Cancer Doesn't Own YouDr. Bouchard's FREE Cancer Screening GuideGuest InfoDr. Bouchard - WebsiteDr. Bouchard - InstagramRelated EpisodesPodcast Ep. 222: Melanie Murphy Richter (Prolon) - Boost Cellular Autophagy, Inflammation Reduction & Weight Loss Fast MimickingPodcast Ep. 204: Natalie Samson - Exploring Integrative Genetic Counseling as a Transformative Healthcare ApproachWork w/Leigh AnnLearn: What is EVOX Therapy?Book:

Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patients treated outside large academic medical centers. In this sponsored episode of The Top Line, host Chris Hayden sits down with Kirk Kaminsky, executive vice president and group president of North American Pharmaceutical Services for McKesson, to examine what this shift means for patients, providers and the industry. Kaminsky explains how advances in cancer science have transformed many diagnoses into long-term conditions, increasing the need for accessible, high-quality care in local communities. He discusses the challenges community practices face as innovation accelerates, including evolving reimbursement models, operational pressures and the adoption of new technologies. The conversation also explores the role of community oncology in expanding access to clinical trials and accelerating research, as well as how artificial intelligence is being used to improve both clinical and administrative workflows. Kaminsky shares his outlook on the next five to 10 years of cancer care and why supporting community oncology will be critical to continued progress. Listen to the full interview to learn more.See omnystudio.com/listener for privacy information.

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

In this episode, we're joined by Dr. Bryce from City of Hope, a leading expert at one of the nation's top cancer research and treatment centers. Dr. Bryce brings deep clinical insight and real-world experience to a wide-ranging conversation on innovation in medicine, patient-centered care, and the future of cancer research. Website: cityofhope.org Instagram: cityofhopeaz   BACK STORY Alan H. Bryce, M.D., joined City of Hope® Cancer Center Phoenix as the chief clinical officer in 2023 and is currently the Interim President of City of Hope Phoenix. As a medical oncologist and researcher, Dr. Bryce holds a dual title as professor of department of molecular medicine at Translational Genomics Research Institute (TGen), also part of City of Hope and located in Phoenix. As an oncologist with City of Hope Cancer Center Phoenix, Dr. Bryce focuses his practice on genitourinary cancers, primarily prostate and testicular cancers, with specialized expertise in genomics, drug development and precision medicine in prostate cancer. Dr. Bryce has been at the forefront of bringing precision medicine to prostate cancer treatment. He is an internationally recognized leader in developing new drugs to aid in the search for a cure for prostate cancer. Dr. Bryce studies the power of leveraging cancer genomics and believes we can treat each patient with the best drug for his individual situation. After attending medical school at Finch University of Health Sciences/Chicago Medical School, Dr. Bryce completed a residency in internal medicine at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine. He then finished medical training as chief fellow in his hematology and medical oncology fellowship at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine. Throughout his career, Dr. Bryce has been widely published and received numerous honors and awards. He is board certified in internal medicine and medical oncology and is a member of several professional organizations, including the American Association of Clinical Oncology (ASCO).    SUBSCRIBE TO ICONIC HOUR If you enjoyed today's podcast, I'd be so appreciative if you'd take two minutes to subscribe, rate and review ICONIC HOUR. It makes a huge difference for our growth. Thanks so much!   ICONIC LIFE MAGAZINE  Stay in touch with ICONIC LIFE magazine. We invite you to join our digital VIP list and SUBSCRIBE!   JOIN OUR ICONIC COMMUNITY Website: iconiclife.com Instagram: @iconiclifemag Facebook: Iconic Life YouTube: ICONIC LIFE   FOLLOW RENEE DEE Instagram: @iconicreneedee LinkedIn: Renee Dee   Thanks for being a part of our community to Live Beautifully.  

Half of us will develop cancer at some point in our lives, according to Cancer Research UK. And the speed of a diagnosis can often be the difference between life and death. Just a one-month delay can raise the risk of death by up to 10%. Yet in England, almost a third of cancer patients wait more than two months to start treatment after an urgent GP referral - twice as many as the target and a trend that's getting worse. As the Westminster government prepares to publish its new 10-year cancer plan - what can we learn from elsewhere in the world? In Denmark, for example, cancer waiting lists have virtually been eliminated and survival rates are rocketing. Niall speaks to Sky's health correspondent Ashish Joshi and Jesper Fisker from the Danish Cancer Society. Producer: Natalie Ktena & Sam Gruet Editor: Mike Bovill

This episode of Lung Cancer Considered, hosted by Dr. Narjust Florez, examines the challenges of delivering lung cancer care in areas affected by war and displacement with guests Dr. Julie Gralow and Dr. Rafal Dziadziuszko. The discussion addresses disrupted diagnosis and treatment, heightened inequities, and unique environmental exposures that may increase lung cancer risk in conflict settings. The episode also highlights emerging opportunities through global collaboration, adaptable care models, and shared responsibility across the oncology community. Guests: Dr. Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO). She is also the founder of the Women's Empowerment Cancer Advocacy Network (WE CAN) and an expert in global oncology. Rafał Dziadziuszko, M.D., Ph.D., professor of medicine, Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland

Narrative Review Examines Integrating Oral Health in Cancer Care for Older AdultsBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/narrative-review-examines-integrating-oral-health-in-cancer-care-for-older-adults/Need CE? Start earning CE credits today at ⁠⁠https://rdh.tv/ce⁠⁠ Get daily dental hygiene articles at ⁠⁠https://www.todaysrdh.com⁠⁠ Follow Today's RDH on Facebook: ⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠Follow Kara RDH on Facebook: ⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠Follow Kara RDH on Instagram: ⁠⁠https://www.instagram.com/kara_rdh/⁠

In this episode, Adam Torres and Majed Mohamed, Head of Community Engagement & Advocacy at Friends of Cancer Patients, talk about reducing stigma, improving early cancer detection, and advancing patient-centered advocacy through awareness, policy engagement, and direct support initiatives in the UAE. About Majed Mohamed A passionate and dedicated Public Health Specialist with a strong foundation in medical sciences, committed to improving health outcomes through strategic advocacy, policy development, and research. Experienced in working across sectors to promote awareness, prevention, and support for patients with NCDs. Focused on enhancing healthcare systems, driving public health initiatives, and contributing to global efforts to improve cancer care. Specializing in patient advocacy, health policy, and research, with a keen interest in fostering partnerships between public and private sectors to create impactful solutions for pressing health challenges. About Friends of Cancer Patients Friends of Cancer Patients charity is a non-profit organization registered at the UAE Ministry of Social Affairs under the ministerial decree No. 427 for the year 2013. FOCP was founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, International Ambassador of the World Cancer Declaration for Union for International Cancer Control (UICC) and International Ambassador for Childhood Cancer for UICC and Founder and Patron of the Friends of Cancer Patients society. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, ⁠Adam Torres⁠ and ⁠Majed Mohamed⁠, Head of Community Engagement & Advocacy at Friends of Cancer Patients, talk about reducing stigma, improving early cancer detection, and advancing patient-centered advocacy through awareness, policy engagement, and direct support initiatives in the UAE. About ⁠Majed Mohamed⁠ A passionate and dedicated Public Health Specialist with a strong foundation in medical sciences, committed to improving health outcomes through strategic advocacy, policy development, and research. Experienced in working across sectors to promote awareness, prevention, and support for patients with NCDs. Focused on enhancing healthcare systems, driving public health initiatives, and contributing to global efforts to improve cancer care. Specializing in patient advocacy, health policy, and research, with a keen interest in fostering partnerships between public and private sectors to create impactful solutions for pressing health challenges. About ⁠Friends of Cancer Patients⁠ Friends of Cancer Patients charity is a non-profit organization registered at the UAE Ministry of Social Affairs under the ministerial decree No. 427 for the year 2013. FOCP was founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, International Ambassador of the World Cancer Declaration for Union for International Cancer Control (UICC) and International Ambassador for Childhood Cancer for UICC and Founder and Patron of the Friends of Cancer Patients society. Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.

In this episode, Anna Liza Rodriguez, Vice President, Nursing and Patient Care Services and Chief Nursing Officer, Fox Chase Cancer Center discusses the organization's ambulatory care excellence model, highlighting role clarity, staffing optimization, and improved care coordination. She also shares priorities for 2026, including nursing innovation, workforce engagement, and more.

In this episode of Plugged In to Public Health, we sit down with James Byrne, assistant professor of radiation oncology and biomedical engineering at the University of Iowa, to explore how interdisciplinary science is reshaping cancer care. Dr. Byrne shares his path through MD-PhD training and explains how his work bridges medicine, engineering, and biology to address some of the biggest challenges in oncology. From oxygen-delivering foams inspired by everyday tools to radiation-protective proteins borrowed from extremophile organisms, this conversation highlights how surprisingly simple concepts can lead to powerful clinical innovations. We also discuss why curing cancer is no longer the only goal. As survival rates improve, protecting patients' long-term quality of life has become just as critical. Dr. Byrne explains how his lab is working to prevent the lasting side effects of cancer treatments, not just treat the disease itself. This episode also offers practical insight for students and early-career researchers interested in innovation, intellectual property, and translational science, including what it takes to move research from the lab bench to clinical trials and beyond. A transcript of this episode will be available here soon. Have a question for our podcast crew or an idea for an episode? You can email them at CPH-GradAmbassador@uiowa.edu You can also support Plugged in to Public Health by sharing this episode and others with your friends, colleagues, and social networks. #publichealth #cancer #oncology #radiationoncology #innovation #biomedicalengineering #healthcare #medicine #treatments #prevention #translationalscience #iowacity

In this podcast, experts Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; and Neeta Pandit-Taskar, MD, MBA, discuss the latest evidence on PSMA PET and RLT, including combination strategies, selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.

This week on Inspire + Move, I'm joined by the brilliant and inspiring Dr. Lori Bouchard, ND. Dr. Lori is a Naturopathic Doctor, bestselling author, cancer care expert, founder of Inside Health Naturopathic Clinic and speaker. Dr. Lori joined me in our home studio for this in-person recording, packed with real stories, powerful insights, and major takeaways on how we define health, and how we can reclaim it.Dr. Lori shares how she built a career rooted in evidence-based naturopathic care, her approach to healing chronic illness and cancer through the gut and mitochondria, and the lifestyle shifts that transformed her own health and happiness as a working mom of three.Tune in to hear more about: • Dr. Lori's unexpected path into cancer care and the patient who changed everything • How your gut and mitochondria drive your energy, immunity, and healing • The dangerous gap between what we think is healthy and what's actually beneficial • Why testing your bloodwork matters more than trends • How moving to Mexico helped Laurie rediscover movement, joy, and boundaries • The role of mindset in both entrepreneurship and radical healingStay tuned for Part 2 of our conversation this week! Dr. Lori is a wealth of wisdom and a force in the wellness world, so let us know what shifts for you after this one and shoot me a DM @AlliArruda.Dr. Lori's LinksWebsite: https://www.drlori.caInstagram: https://www.instagram.com/drloribouchard_nd/Book- Love, Medicine and Miracles by Bernie S. Siegel: https://amzn.to/4qzHezPWant to Make More Money in 2026? You Need to Be Seen!Get on the waitlist for my NEW 6-Week Visibility Accelerator Program:https://www.inspireandmove.ca/visibility-accelerator-waitlistLet's Connect!• INSPIRE + MOVE EVENTS• Instagram• Private Coaching• Website• Facebook• TikTok

Inside Oncology Nursing with guest Tracy Battaglia Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Inside Oncology Nursing with guest Tracy Battaglia Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Cancer is among the leading causes of death among firefighters. By reducing firefighters' exposure risks, encouraging regular cancer screenings and providing education, navigation and support, the Firefighters Cancer Collaborative aims to change that and save more lives. Richard Brown, MD, Medical Director for the Brian D. Jellison Cancer Institute at SMH, and Town of Longboat Key Fire Chief Paul Dezzi, explain the collaborative's mission and discuss the successes so far.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Send us a textWhat does truly personalized cancer care actually look like in the years ahead? In this clip from our episode “When AI Spots What Doctors Miss”, HealthBiz Podcast host David Williams speaks with Steve Brown, Founder and CEO of CureWise, about how AI and full-genome sequencing could enable truly individualized cancer treatment. Listen to the full episode here

In this episode of Outside the OR, we explore how collaboration between the Society of Surgical Oncology (SSO) and the American College of Surgeons Cancer Surgery Standards Program (ACS CSSP) is helping raise the bar for cancer care nationwide. Joined by Dr. Matthew H.G. Katz and Dr. Tina J. Hieken, we discuss how shared standards, multidisciplinary alignment, and surgeon leadership translate into better support for surgeons, and better outcomes for patients. Tune in for a thoughtful conversation on why collaboration matters and how collective efforts are shaping the future of cancer surgery.

In this episode, Dr. Brian Druker of the OHSU Knight Cancer Institute along with Elizabeth Liebow and Jim Donohue of ECG Management Consultants, discuss the rising demand for cancer care, the human experience of diagnosis, and the need for smarter collaborations between providers, payers, and policymakers to expand access, improve early detection, and align care delivery with what patients need most.This episode is sponsored by ECG Management Consultants.

In this episode, we're joined by Rick Hill, a Clinic Revenue Strategist for Richardson Nutritional Center, sales consultant at Hill Distributing, author, speaker, and former radio talk show host. With over 28 years of experience in sales leadership, Rick has helped startup companies grow their customer base and revenue while working closely in the integrative and alternative health space.  Listen in as Rick shares his personal journey and professional evolution, including his role as co-inventor of AirSource, a home air purification system that generated $50 million in sales in its first year with Shaklee Corporation. As an author of Too Young to Die: Dramatic Use of Laetrile to Conquer Terminal Cancer and The Cancer Conundrum: Stop Dying—Start Living, Rick has spent decades speaking publicly about patient stories, nutrition, enzymes, and complementary approaches to wellness. This conversation covers: How Rick's story has shaped his current ambitions.  Why patients explore integrative and nutritional approaches to health The role of enzymes, nutrition, and lifestyle in wellness conversations Navigating controversial topics in alternative health responsibly Hit play to gain insights into why alternative health discussions persist, how personal experience influences belief systems, and what it means to ask difficult questions about wellness in today's medical landscape!  You can follow along with Rick by visiting www.owwc.org/b17works.